UK neurologists have been slow to prescribe beta interferon and other potentially disease-modifying drugs for multiple sclerosis (MS). We have been constrained by our notorious conservatism, which is in part based on our demand for good evidence before changing practice, particularly when it comes to very expensive therapeutic interventions such as beta interferon. But there has been another constraint – the UK National Health Service (NHS) has a centralized command and control system (which I personally rather approve of) that would not sanction the prescription of beta interferon because of its very high cost. After all, to prescribe even just to those patients conforming to the Association of British Neurologists (ABN) guidelines would cost roughly £120 million per annum, enough to fund about 1200 new consultant neurologists (which would quadruple our present number), or 4000 physiotherapists, or 8000 medical secretaries. It is all very well for individual neurologists to stamp their
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Disease modifying therapies for relapsing multiple sclerosis
- Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
- Drug treatment of multiple sclerosis
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
- Disease-modifying therapies for multiple sclerosis
- ▼Natalizumab for multiple sclerosis?
- Diagnosis and disease modifying treatments in multiple sclerosis
- Multiple sclerosis
- Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
- ▼Teriflunomide for multiple sclerosis